Researchers discovered that a receptor protein called CHRM1 plays an important role in prostate cancer cells' resistance to docetaxel, a routinely used chemotherapeutic treatment to treat advanced cancer that has progressed beyond the prostate.
According to the Brigham researchers' next-generation sequencing, changing existing cancer care standards might allow around 6,000 more patients in the United States to benefit from immunotherapy treatment each year.
A revolutionary study performed by UNIST's Department of Biological Sciences' Professor Sebyung Kang and Professor Sung Ho Park has shown a significant advance in cancer therapy. The study team has successfully generated novel "NK cell-engaging nanodrones" capable of specifically targeting
A new study published in Science Advances explains how an enzyme called SMYD3 may play a role in the advancement of prostate cancer to a more hazardous and aggressive stage.
For far too long, cancer treatment has been a double-edged sword, with treatments designed to target cancer cells sometimes harming healthy cells as well.
An antibody developed in the lab of Cold Spring Harbour Laboratory Professor Nicholas Tonks can inhibit an enzyme that may aid in the spread of some breast tumours. With additional research, the antibody could provide a viable therapeutic treatment for the same breast tumours.
For far too long, cancer treatment has been a two-edged sword, with therapies designed to target cancer cells frequently wreaking damage on good cells as well.
In theory, a team from the University of Massachusetts Amherst proved that a protein antigen from a childhood vaccine may be administered into the cells of a malignant tumour to reorient the body's immune system against the cancer, effectively stopping it and preventing its recurrence.
According to a recent study, a new therapy regimen safely reduced the growth of pancreatic cancer in mice by stopping the cancer cells from scavenging for fuel.